BioSpace News Archive

Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of its 2022 Annual Meeting of Stockholders to be held on Thursday, December 1, 2022 beginning at 11:00 a.m. ET.

Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer, announced the appointment of Amy Levin, RAC, as Vice President of Regulatory Affairs.

Alimera Sciences, Inc. announces findings from a recent meeting where data demonstrated a high level of agreement among retina specialists on the role of inflammation in the pathophysiology of diabetic retinopathy and diabetic macular edema, injection burden and patient adherence, and efficacy and safety of ILUVIEN® 0.19 mg sustained release intravitreal implant.

Candel Therapeutics, Inc. (“Candel” or “the Company”) (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced it will host a virtual Research and Development (R&D) Day from 11:00 am – 1:30 pm ET on Tuesday, December 6, 2022.

Applied Genetic Technologies Corporation, announced that a portfolio company of Syncona Limited has extended the expiration of its previously announced tender offer to purchase all of the issued and outstanding shares of AGTC common stock for $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights upon the achievement of specified milestones.

Capstone Development Services Company LLC (“Capstone”) announced today that a biosimilar version of human insulin received authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) and a Notice of Compliance from Health Canada.

BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that more than 316 patients have enrolled in its Phase 3 trial, thereby achieving its trial enrollment target.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today reported its third quarter 2022 financial results and operational highlights.

Envisagenics today announced a research collaboration agreement with Bristol Myers Squibb (NYSE: BMY).

Rgenta Therapeutics Inc. announced today that it closed a $52 million Series A round led by AZ-CICC Healthcare Investment Fund with participation from all existing investors and new investors.